Chronic Hepatitis C treatment for genotype 2 or 3 in Brazil: cost effectiveness analysis of peginterferon plus ribavirin as first choice treatment . Brazilian Journal of Pharmaceutical Sciences, [S. l.], v. 50, n. 2, p. 345–352, 2014. DOI: 10.1590/S1984-82502014000200014. Disponível em: https://periodicos.usp.br/bjps/article/view/86942.. Acesso em: 2 jun. 2024.